These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9617979)

  • 41. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine.
    Shimodozono M; Kawahira K; Kamishita T; Ogata A; Tohgo S; Tanaka N
    Int J Neurosci; 2002 Oct; 112(10):1173-81. PubMed ID: 12587520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Review of double-blind studies comparing SSRI and SNRI].
    Suzuki E; Maruta S
    Seishin Shinkeigaku Zasshi; 2004; 106(10):1203-17. PubMed ID: 15669214
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia.
    Taiminen TJ; Syvälahti E; Saarijärvi S; Niemi H; Lehto H; Ahola V; Salokangas RK
    Int Clin Psychopharmacol; 1997 Jan; 12(1):31-5. PubMed ID: 9179631
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis.
    Sepehry AA; Potvin S; Elie R; Stip E
    J Clin Psychiatry; 2007 Apr; 68(4):604-10. PubMed ID: 17474817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Int Clin Psychopharmacol; 2003 Nov; 18(6):305-13. PubMed ID: 14571150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
    Silver H; Nassar A; Aharon N; Kaplan A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients.
    Hewer W; Rost W; Gattaz WF
    Eur Arch Psychiatry Clin Neurosci; 1995; 246(1):1-6. PubMed ID: 8773212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity.
    Atkinson JH; Slater MA; Wahlgren DR; Williams RA; Zisook S; Pruitt SD; Epping-Jordan JE; Patterson TL; Grant I; Abramson I; Garfin SR
    Pain; 1999 Nov; 83(2):137-45. PubMed ID: 10534584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thyroid hormones, body temperature, and antidepressant treatment.
    Höflich G; Kasper S; Danos P; Schmidt R
    Biol Psychiatry; 1992 Apr; 31(8):859-62. PubMed ID: 1643199
    [No Abstract]   [Full Text] [Related]  

  • 58. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
    Ueda N; Yoshimura R; Shinkai K; Nakamura J
    Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine.
    Coleman BS; Block BA
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):475-8. PubMed ID: 6819596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.